HIGHLIGHTS
- who: Sebastiano Barco from the University of Texas at Austin, United States have published the research: Untargeted LC-HRMS Based-Plasma Metabolomics Reveals 3-O-Methyldopa as a New Biomarker of Poor Prognosis in High-Risk Neuroblastoma, in the Journal: (JOURNAL)
- what: The authors show the application of a HRMS metabolomic approach to NB. The authors assessed the prognostic value of 3-OMD in clinically relevant groups of NB patients whose stratification was rarely reported . In the present study, differential expression analysis from plasma samples of patients and healthy controls identified metabolites, including 3-O . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.